Loading
Life sciences · Journal article
Livers · October 1, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background: Uveal melanoma (UM) typically metastasizes to the liver for yet unclear reasons. Hepatic steatosis influences metastasis in several cancer entities, and increased lipid synthesis and metabolism in the cancer tissue promotes tumor progression. The aim of this study was to investigate the association of MRI-derived lipid content in non-tumorous liver tissue and liver metastases with the biological behavior and metastatic characteristics of UM liver metastases, as well as with survival in patients with metastatic UM. Methods: The lipid content in the liver and hepatic metastases was quantified by multiparametric magnetic resonance imaging in 46 patients with metastasized UM prior to therapy. The perfusion characteristics of liver metastases were assessed using contrast-enhanced MRI-derived arterial enhancement ratios (metastasis-to-aorta signal intensity ratio), and diffusion-weighted imaging was used to evaluate tissue cellularity in metastatic tissues. Results: We found a significant correlation between body mass index (BMI) and hepatic lipid content (Spearman’s r = 0.47; unadjusted p = 0.0027; adjusted p = 0.03; 95% CI: 0.17 to 0.69), between the hepatic lipid content and volume of the metastases (Spearman’s r = −0.42; unadjusted p = 0.007; adjusted p = 0.036; 95% CI: −0.65 to −0.12) after correction for multiple testing. Higher hepatic lipid content (≥5%) was associated with improved survival with stage IV (p = 0.00043), whereas metastatic lipid content showed no significant association in Kaplan–Meier analysis. In Cox proportional hazards analysis, higher hepatic lipid content was associated with reduced hazard ratio of death independent of tebentafusp treatment (without tebentafusp: p = 0.0034; HR = 0.497; with tebentafusp: p = 0.0016; HR = 0.318) while no consistent association was observed for metastatic lipid content. Conclusions: Metabolic changes associated with a high BMI may contribute to lipid-induced changes in the liver microenvironment that may play a role in the tumor biology of hepatic metastases in patients with UM.